#1 Clinical Trials Search in Europe

Cefoxitin

Cefoxitin, a second-generation cephalosporin antibiotic, is being studied in several clinical trials for its effectiveness in treating various infections and as a prophylactic measure in surgical procedures. These trials aim to evaluate cefoxitin’s efficacy, safety, and optimal dosing strategies in different patient populations and medical conditions.

Table of Contents

What is Cefoxitin?

Cefoxitin is an antibiotic medication that belongs to a class of drugs called cephamycins[1]. It’s a type of beta-lactam antibiotic, which means it’s related to penicillin but has some unique properties that make it effective against certain types of bacteria[1]. Cefoxitin was developed in the 1970s but has gained renewed interest in recent years due to its effectiveness against certain antibiotic-resistant bacteria[1].

Uses of Cefoxitin

Cefoxitin is used to treat or prevent various types of bacterial infections. Some of the common uses include:

  • Surgical site infections: Cefoxitin is often used to prevent infections after certain types of surgery, particularly abdominal surgeries like colorectal surgery[2] and pancreatic surgery[3].
  • Urinary tract infections: It’s being studied for use in treating urinary tract infections caused by certain antibiotic-resistant bacteria[4].
  • Pelvic infections: Cefoxitin may be used to prevent infections after childbirth, particularly in women who have had complicated deliveries[5].
  • Appendicitis: Some studies are exploring whether cefoxitin can be used as part of antibiotic treatment for appendicitis, potentially avoiding the need for surgery in some cases[6].

How Cefoxitin Works

Cefoxitin works by interfering with the way bacteria build their cell walls. It has a special structure that includes an alpha-methoxy group, which makes it resistant to certain enzymes (called beta-lactamases) that some bacteria use to defend themselves against antibiotics[1]. This means cefoxitin can be effective against some bacteria that have become resistant to other antibiotics.

Administration Methods

Cefoxitin is typically given in a hospital setting, usually through an intravenous (IV) line directly into the bloodstream. The dosage and duration of treatment can vary depending on the type and severity of the infection being treated. Some common administration methods include:

  • Single dose: For preventing surgical infections, cefoxitin is often given as a single dose shortly before surgery[3].
  • Multiple doses: For treating active infections, cefoxitin may be given every 6-8 hours for several days[7].
  • Continuous infusion: Some studies are exploring whether giving cefoxitin as a continuous infusion might be more effective for preventing infections[2].

Effectiveness and Ongoing Research

Cefoxitin has been shown to be effective against many types of bacteria, including some that are resistant to other antibiotics. However, researchers are continually studying how to use it most effectively. Some areas of ongoing research include:

  • Optimal dosing: Studies are looking at the best ways to give cefoxitin, including how much to give and how often[7].
  • Comparison with other antibiotics: Researchers are comparing cefoxitin to other antibiotics to see which is most effective for different types of infections[4][3].
  • Use in specific patient groups: Some studies are looking at how well cefoxitin works in specific groups of patients, such as obese patients undergoing surgery[7] or HIV-positive women giving birth[8].

Potential Side Effects

Like all medications, cefoxitin can cause side effects in some people. Common side effects may include nausea, diarrhea, or pain at the injection site. More serious side effects are rare but can include allergic reactions or severe diarrhea. It’s important to discuss potential side effects with your healthcare provider before receiving cefoxitin[7].

Aspect Details
Main Indications ESBL-producing E. coli infections, surgical prophylaxis
Administration Methods Intravenous bolus, continuous infusion, intermittent dosing
Key Advantages Effective against ESBL-producing bacteria, narrower spectrum, potential cost savings
Special Populations Obese patients undergoing bariatric surgery
Outcome Measures Clinical/microbiological response, SSI rates, pharmacokinetics, antibiotic resistance
Comparative Studies Cefoxitin vs. imipenem/cilastatin, cefoxitin vs. piperacillin-tazobactam
Dosing Strategies Varied by trial and patient population (e.g., 2g every 6 hours, 4g loading dose in obese patients)

FAQ

  • What is cefoxitin used for in clinical trials? Cefoxitin is being studied for treating urinary tract infections caused by ESBL-producing E. coli, as antibiotic prophylaxis in surgeries like colorectal and bariatric procedures, and for preventing postpartum infections after perineal tear repairs.
  • How is cefoxitin administered in these trials? Administration methods vary by trial, including intravenous bolus doses, continuous infusions, and intermittent dosing. For example, in colorectal surgery, researchers are comparing intermittent administration to a loading bolus followed by continuous infusion.
  • What are the potential benefits of using cefoxitin over other antibiotics? Cefoxitin may offer advantages such as effectiveness against ESBL-producing bacteria, a narrower antibacterial spectrum to reduce resistance, and potential cost savings compared to newer antibiotics like carbapenems.
  • Are there any special considerations for cefoxitin use in obese patients? Yes, one trial is specifically studying cefoxitin dosing in severely obese patients undergoing bariatric surgery, as obesity can affect antibiotic pharmacokinetics and potentially lead to underdosing.
  • What are researchers measuring to determine cefoxitin's effectiveness? Researchers are evaluating factors such as clinical and microbiological response rates, surgical site infection rates, pharmacokinetic parameters like serum concentrations, and the impact on the emergence of antibiotic-resistant bacteria.

Ongoing Clinical Trials on Cefoxitin

  • Study on the Effectiveness of Clofazimine and Drug Combination for Treating Mycobacterium abscessus Lung Disease in Adult Patients

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study comparing amoxicillin/clavulanic acid treatment versus surgery for children with uncomplicated appendicitis

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • ESBL-producing E. coli: Escherichia coli bacteria that produce extended-spectrum beta-lactamases, enzymes that can break down many common antibiotics, making these infections more difficult to treat.
  • Carbapenem: A class of powerful antibiotics often used as a last resort for treating resistant bacterial infections.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Surgical site infection (SSI): An infection that occurs at or near a surgical incision within 30 days of the procedure or within 90 days if an implant is placed.
  • Antibiotic prophylaxis: The use of antibiotics before, during, or after a procedure or activity to prevent infectious complications.
  • Pyelonephritis: A type of urinary tract infection that affects one or both kidneys.
  • Microdialysis: A technique used to measure the concentration of substances in the fluid between cells in various tissues.
  • Bariatric surgery: Surgical procedures performed on the stomach or intestines to induce weight loss in severely obese individuals.
  • Cephamycin: A subclass of beta-lactam antibiotics that includes cefoxitin, characterized by their resistance to certain types of beta-lactamase enzymes.
  • Minimum inhibitory concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of a bacterium.

References

  1. https://clinicaltrials.gov/study/NCT01820793
  2. https://clinicaltrials.eu/trial/study-on-cefoxitin-and-sodium-chloride-for-preventing-infections-after-colorectal-surgery/
  3. https://clinicaltrials.gov/study/NCT03269994
  4. https://clinicaltrials.gov/study/NCT02474706
  5. https://clinicaltrials.gov/study/NCT00186082
  6. https://clinicaltrials.gov/study/NCT00469430
  7. https://clinicaltrials.gov/study/NCT03306290
  8. https://clinicaltrials.gov/study/NCT00343317